Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Net Assets

Latest as of March 2026: CN¥97.08 Million CNY ≈ $14.21 Million USD

Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has net assets worth CN¥97.08 Million CNY (≈ $14.21 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥464.88 Million ≈ $68.03 Million USD) and total liabilities (CN¥367.80 Million ≈ $53.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hangzhou TianMuShan Pharmaceutical Enter (600671) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥97.08 Million
% of Total Assets 20.88%
Annual Growth Rate 0.26%
5-Year Change 45.59%
10-Year Change 42.02%
Growth Volatility 206.63

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Hangzhou TianMuShan Pharmaceutical Enter to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2025)

The table below shows the annual net assets of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2025. For live valuation and market cap data, see Hangzhou TianMuShan Pharmaceutical Enter market cap and net worth.

Year Net Assets Change
2025-12-31 CN¥93.99 Million
≈ $13.75 Million		 +10.55%
2024-12-31 CN¥85.02 Million
≈ $12.44 Million		 +51.96%
2023-12-31 CN¥55.95 Million
≈ $8.19 Million		 +1148.93%
2022-12-31 CN¥4.48 Million
≈ $655.53K		 -93.06%
2021-12-31 CN¥64.56 Million
≈ $9.45 Million		 -30.83%
2020-12-31 CN¥93.33 Million
≈ $13.66 Million		 -30.00%
2019-12-31 CN¥133.33 Million
≈ $19.51 Million		 +63.34%
2018-12-31 CN¥81.62 Million
≈ $11.94 Million		 -15.21%
2017-12-31 CN¥96.27 Million
≈ $14.09 Million		 +45.45%
2016-12-31 CN¥66.18 Million
≈ $9.68 Million		 +5.46%
2015-12-31 CN¥62.76 Million
≈ $9.18 Million		 -26.38%
2014-12-31 CN¥85.25 Million
≈ $12.47 Million		 -10.51%
2013-12-31 CN¥95.26 Million
≈ $13.94 Million		 +2.70%
2012-12-31 CN¥92.76 Million
≈ $13.57 Million		 -49.27%
2011-12-31 CN¥182.84 Million
≈ $26.75 Million		 +18.62%
2010-12-31 CN¥154.14 Million
≈ $22.55 Million		 -17.90%
2009-12-31 CN¥187.74 Million
≈ $27.47 Million		 -21.87%
2008-12-31 CN¥240.30 Million
≈ $35.16 Million		 -15.07%
2007-12-31 CN¥282.93 Million
≈ $41.40 Million		 +19.66%
2006-12-31 CN¥236.44 Million
≈ $34.60 Million		 -1.23%
2005-12-31 CN¥239.39 Million
≈ $35.03 Million		 -5.14%
2004-12-31 CN¥252.36 Million
≈ $36.93 Million		 +4.01%
2003-12-31 CN¥242.64 Million
≈ $35.51 Million		 -4.17%
2002-12-31 CN¥253.20 Million
≈ $37.05 Million		 +0.62%
2001-12-31 CN¥251.63 Million
≈ $36.82 Million		 +0.14%
2000-12-31 CN¥251.29 Million
≈ $36.77 Million		 +2.94%
1999-12-31 CN¥244.10 Million
≈ $35.72 Million		 +3.56%
1998-12-31 CN¥235.71 Million
≈ $34.49 Million		 +4.64%
1997-12-31 CN¥225.25 Million
≈ $32.96 Million		 +11.78%
1996-12-31 CN¥201.52 Million
≈ $29.49 Million		 +15.80%
1995-12-31 CN¥174.02 Million
≈ $25.46 Million		 --
1994-12-31 CN¥0.00
≈ $0.00		 --
1993-12-31 CN¥86.48 Million
≈ $12.65 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2763.6% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components CN¥308.75 Million 441.03%
Total Equity CN¥70.01 Million 100.00%

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Market Cap

The table below lists competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd ranked by their market capitalization.

Company Market Cap
BRC Group Holdings, Inc.
NASDAQ:RILY
 $320.07 Million
New Providence Acquisition Corp. III Class A Ordinary Shares
NASDAQ:NPAC
 $320.30 Million
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
 $320.37 Million
Patel Engineering Limited
NSE:PATELENG
 $320.39 Million
Unitech Computer Co Ltd
TW:2414
 $320.00 Million
Ld Intelligent Technology Co Ltd
SHE:300883
 $319.99 Million
Tus Pharmaceutical Group Co Ltd
SHE:000590
 $319.94 Million
Global Standard Technology Limited
KQ:083450
 $319.76 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 52,383,884 to 70,006,502, a change of 17,622,618 (33.6%).
  • Net income of 17,622,618 contributed positively to equity growth.
  • Dividend payments of 6,497,577 reduced retained earnings.
  • Other factors increased equity by 6,497,578.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥17.62 Million +25.17%
Dividends Paid CN¥6.50 Million -9.28%
Other Changes CN¥6.50 Million +9.28%
Total Change CN¥- 33.64%

Book Value vs Market Value Analysis

This analysis compares Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 31.24x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 25.29x to 31.24x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.71 CN¥17.96 x
1994-12-31 CN¥0.91 CN¥17.96 x
1995-12-31 CN¥1.09 CN¥17.96 x
1996-12-31 CN¥1.26 CN¥17.96 x
1997-12-31 CN¥1.32 CN¥17.96 x
1998-12-31 CN¥1.39 CN¥17.96 x
1999-12-31 CN¥1.43 CN¥17.96 x
2000-12-31 CN¥1.43 CN¥17.96 x
2001-12-31 CN¥1.41 CN¥17.96 x
2002-12-31 CN¥1.41 CN¥17.96 x
2003-12-31 CN¥1.34 CN¥17.96 x
2004-12-31 CN¥1.39 CN¥17.96 x
2005-12-31 CN¥1.31 CN¥17.96 x
2006-12-31 CN¥1.55 CN¥17.96 x
2007-12-31 CN¥1.84 CN¥17.96 x
2008-12-31 CN¥1.65 CN¥17.96 x
2009-12-31 CN¥1.42 CN¥17.96 x
2010-12-31 CN¥1.12 CN¥17.96 x
2011-12-31 CN¥1.40 CN¥17.96 x
2012-12-31 CN¥0.63 CN¥17.96 x
2013-12-31 CN¥0.74 CN¥17.96 x
2014-12-31 CN¥0.58 CN¥17.96 x
2015-12-31 CN¥0.48 CN¥17.96 x
2016-12-31 CN¥0.48 CN¥17.96 x
2017-12-31 CN¥0.57 CN¥17.96 x
2018-12-31 CN¥0.42 CN¥17.96 x
2019-12-31 CN¥0.84 CN¥17.96 x
2020-12-31 CN¥0.59 CN¥17.96 x
2021-12-31 CN¥0.36 CN¥17.96 x
2022-12-31 CN¥-0.12 CN¥17.96 x
2023-12-31 CN¥0.30 CN¥17.96 x
2024-12-31 CN¥0.43 CN¥17.96 x
2025-12-31 CN¥0.57 CN¥17.96 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 25.17%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.32%
  • • Asset Turnover: 0.48x
  • • Equity Multiplier: 6.31x
  • Recent ROE (25.17%) is above the historical average (-6.54%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 11.52% 23.18% 0.38x 1.31x CN¥1.31 Million
1994 10.69% 27.24% 0.30x 1.33x CN¥1.00 Million
1995 7.79% 20.41% 0.25x 1.52x CN¥-3.81 Million
1996 10.37% 28.11% 0.29x 1.29x CN¥745.14K
1997 10.06% 22.33% 0.32x 1.41x CN¥121.17K
1998 10.26% 17.49% 0.40x 1.47x CN¥563.65K
1999 6.09% 10.06% 0.41x 1.49x CN¥-8.90 Million
2000 1.10% 2.64% 0.23x 1.79x CN¥-20.18 Million
2001 1.50% 2.33% 0.35x 1.82x CN¥-19.07 Million
2002 0.88% 1.24% 0.42x 1.67x CN¥-20.40 Million
2003 -5.48% -5.93% 0.57x 1.63x CN¥-32.95 Million
2004 3.12% 3.29% 0.59x 1.62x CN¥-15.21 Million
2005 1.77% 1.54% 0.64x 1.80x CN¥-17.08 Million
2006 0.19% 0.15% 0.74x 1.71x CN¥-20.24 Million
2007 6.63% 5.70% 0.64x 1.82x CN¥-7.69 Million
2008 1.81% 1.61% 0.69x 1.64x CN¥-18.40 Million
2009 -30.27% -21.29% 0.75x 1.90x CN¥-69.50 Million
2010 -6.28% -3.77% 0.73x 2.27x CN¥-22.90 Million
2011 15.74% 9.54% 0.77x 2.13x CN¥9.64 Million
2012 -116.50% -38.78% 0.77x 3.88x CN¥-96.47 Million
2013 2.69% 0.75% 0.87x 4.15x CN¥-5.73 Million
2014 3.45% 1.82% 0.52x 3.63x CN¥-5.16 Million
2015 -37.67% -22.73% 0.34x 4.90x CN¥-27.26 Million
2016 2.06% 0.98% 0.40x 5.19x CN¥-4.68 Million
2017 12.31% 4.62% 0.39x 6.81x CN¥1.53 Million
2018 -19.18% -2.76% 0.75x 9.33x CN¥-15.02 Million
2019 49.78% 17.06% 0.56x 5.18x CN¥40.50 Million
2020 -55.62% -19.61% 0.47x 6.07x CN¥-47.80 Million
2021 -65.96% -20.26% 0.37x 8.91x CN¥-34.32 Million
2022 0.00% -62.00% 0.36x 0.00x CN¥-66.05 Million
2023 -103.06% -31.43% 0.35x 9.32x CN¥-41.99 Million
2024 29.10% 7.02% 0.49x 8.43x CN¥10.01 Million
2025 25.17% 8.32% 0.48x 6.31x CN¥10.62 Million

Industry Comparison

This section compares Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $3,454,789,497
  • Average return on equity (ROE) among peers: 9.06%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) CN¥97.08 Million 11.52% 3.79x $320.05 Million
Zhejiang Int'L Group Co Ltd (000411) $172.72 Million 3.54% 3.43x $732.38 Million
Zhejiang Zhenyuan Share Co Ltd (000705) $1.39 Billion 4.40% 0.48x $308.51 Million
Hunan Jingfeng Pharmaceutical (000908) $329.66 Million 0.90% 1.55x $750.55 Million
Hubei Guangji Pharmaceutical Co Ltd (000952) $481.54 Million 6.36% 0.40x $302.41 Million
Yifan Xinfu Pharmaceutical Co Ltd (002019) $320.93 Million 6.38% 0.61x $1.73 Billion
Guangdong Jiaying Pharmaceutical Co Ltd (002198) $82.63 Million 26.76% 0.45x $247.30 Million
Sichuan Kelun Pharmaceutical Co Ltd (002422) $26.74 Billion 10.98% 0.40x $8.36 Billion
Chongqing Lummy Pharmaceutical (300006) $1.69 Billion 1.22% 0.84x $760.20 Million
Zhejiang Jolly Pharmaceutical Co Ltd (300181) $2.76 Billion 9.89% 0.32x $1.32 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) $582.91 Million 20.21% 0.05x $1.63 Billion

About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

SHG:600671 China Drug Manufacturers - General
Market Cap
$320.05 Million
CN¥2.19 Billion CNY
Market Cap Rank
#14598 Global
#4355 in China
Share Price
CN¥17.96
Change (1 day)
+9.98%
52-Week Range
CN¥13.07 - CN¥22.50
All Time High
CN¥37.82
Categories
Companies in China Drug Manufacturers - General
About

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared sl… Read more